Press releases

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium

CE Mark for CONFIENT™ implantable cardioverter defibrillator (ICD) represents first Boston Scientific-branded cardiac rhythm management device to treat sudden cardiac death

A live webcast and replay of the October 19 conference call will be available

Data reflects the experience from the first 15,000 patients monitored wirelessly on the LATITUDE® Patient Management System

With the election of Mr. Elliott, the Boston Scientific Board increases to 15 members

Analysis of TAXUS II, IV, V and VI trials found paclitaxel-eluting stents had similar clinical outcomes in women and men, despite women’s higher risk profile